Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Perindopril.

K Alfakih1, A S Hall

  • 1BHF Heart Research Centre, G Floor, Jubilee Wing, The Leeds General Infirmary, Leeds, LS1 3EX, UK.

Expert Opinion on Pharmacotherapy
|December 24, 2005
PubMed
Summary
This summary is machine-generated.

Perindopril, an ACE inhibitor, effectively prevents recurrent stroke and improves outcomes after heart attack. It also benefits patients with stable coronary artery disease or hypertension, showing significant cardiovascular risk reduction.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association of multimorbidity and changes in health-related quality of life following myocardial infarction: a UK multicentre longitudinal patient-reported outcomes study.

BMC medicine·2021
Same author

ESC 2019 guidelines on chronic coronary syndromes: could calcium scoring improve detection of coronary artery disease in patients with low risk score. Findings from a retrospective cohort of patients in a district general hospital.

JRSM cardiovascular disease·2021
Same author

Evaluation of the Methods and Management of Acute Coronary Events (EMMACE)-3: protocol for a longitudinal study.

BMJ open·2015
Same author

Mortality and missed opportunities along the pathway of care for ST-elevation myocardial infarction: a national cohort study.

European heart journal. Acute cardiovascular care·2014
Same author

The development of the NZ-based international upper limb surgery registry.

Spinal cord·2014
Same author

Trends in hospital treatments, including revascularisation, following acute myocardial infarction, 2003-2010: a multilevel and relative survival analysis for the National Institute for Cardiovascular Outcomes Research (NICOR).

Heart (British Cardiac Society)·2014
Same journal

Pharmacotherapeutic interventions for pediatric ulcerative colitis.

Expert opinion on pharmacotherapy·2026
Same journal

The rise and fall of TRPV1-targeted analgesia in osteoarthritis: a critical appraisal.

Expert opinion on pharmacotherapy·2026
Same journal

Dopamine transporter and beyond: evolving targets and combination strategies in stimulant use disorder.

Expert opinion on pharmacotherapy·2026
Same journal

GnRH antagonists for the treatment of fibroids and adenomyosis, current evidence and future perspectives.

Expert opinion on pharmacotherapy·2026
Same journal

Pharmacotherapeutic strategies for the management of congenital adrenal hyperplasia.

Expert opinion on pharmacotherapy·2026
Same journal

Current advances in pharmacotherapeutic strategies for the treatment of complicated intra-abdominal infections.

Expert opinion on pharmacotherapy·2026
See all related articles

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Clinical Trials

Background:

  • Perindopril is a third-generation ACE inhibitor with unique properties.
  • ACE inhibitors are well-established for treating cardiovascular diseases.
  • Previous studies like PROGRESS and PREAMI demonstrated perindopril's efficacy.

Purpose of the Study:

  • To evaluate the efficacy of perindopril in secondary stroke prevention.
  • To assess the benefits of perindopril in elderly patients post-myocardial infarction.
  • To investigate perindopril's impact on cardiovascular risk in stable coronary artery disease and hypertension patients.

Main Methods:

  • The Perindopril Protection Against Recurrent Stroke Study (PROGRESS).
  • The Perindopril and Remodelling in Elderly with Acute Myocardial Infarction (PREAMI) trial.

Related Experiment Videos

  • The European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease (EUROPA) and the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).

    • Main Results:

    • Perindopril demonstrated benefit in secondary stroke prevention.
    • Routine use of perindopril is supported after myocardial infarction in the elderly.
    • Perindopril improved prognosis in patients with stable coronary artery disease or hypertension, independent of statin therapy.

    Conclusions:

    • Perindopril offers significant cardiovascular risk reduction in diverse patient groups.
    • The benefits of perindopril are substantial and relevant to modern clinical practice.
    • Perindopril may act complementarily with other therapies like statins for plaque stabilization.